Literature DB >> 9988171

Serologic survey among hospital and health center workers during the Ebola hemorrhagic fever outbreak in Kikwit, Democratic Republic of the Congo, 1995.

O Tomori1, J Bertolli, P E Rollin, Y Fleerackers, Y Guimard, A De Roo, H Feldmann, F Burt, R Swanepoel, S Killian, A S Khan, K Tshioko, M Bwaka, R Ndambe, C J Peters, T G Ksiazek.   

Abstract

From May to July 1995, a serologic and interview survey was conducted to describe Ebola hemorrhagic fever (EHF) among personnel working in 5 hospitals and 26 health care centers in and around Kikwit, Democratic Republic of the Congo. Job-specific attack rates estimated for Kikwit General Hospital, the epicenter of the EHF epidemic, were 31% for physicians, 11% for technicians/room attendants, 10% for nurses, and 4% for other workers. Among 402 workers who did not meet the EHF case definition, 12 had borderline positive antibody test results; subsequent specimens from 4 of these tested negative. Although an old infection with persistent Ebola antibody production or a recent atypical or asymptomatic infection cannot be ruled out, if they occur at all, they appear to be rare. This survey demonstrated that opportunities for transmission of Ebola virus to personnel in health facilities existed in Kikwit because blood and body fluid precautions were not being universally followed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988171     DOI: 10.1086/514307

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Mapping a Filoviral Serologic Footprint in the Democratic Republic of the Congo: Who Goes There?

Authors:  Ian Crozier
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

2.  Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit.

Authors:  P S C Rees; L E M Lamb; T C Nicholson-Roberts; C N Ardley; M S Bailey; D E Hinsley; T E Fletcher; S J Dickson
Journal:  Intensive Care Med       Date:  2015-03-12       Impact factor: 17.440

3.  Protecting healthcare personnel from acquiring Ebola virus disease.

Authors:  David J Weber; William A Fischer; David A Wohl; William A Rutala
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10       Impact factor: 3.254

Review 4.  Considerations for use of Ebola vaccine during an emergency response.

Authors:  Jenny A Walldorf; Emily A Cloessner; Terri B Hyde; Adam MacNeil
Journal:  Vaccine       Date:  2017-09-07       Impact factor: 3.641

Review 5.  Ebola and Marburg hemorrhagic fevers: neglected tropical diseases?

Authors:  Adam MacNeil; Pierre E Rollin
Journal:  PLoS Negl Trop Dis       Date:  2012-06-26

6.  Ebola outbreak in rural West Africa: epidemiology, clinical features and outcomes.

Authors:  Silvia Dallatomasina; Rosa Crestani; James Sylvester Squire; Hilde Declerk; Grazia Marta Caleo; Anja Wolz; Kathryn Stinson; Gabriela Patten; Raphael Brechard; Osman Bamba-Moi Gbabai; Armand Spreicher; Michel Van Herp; Rony Zachariah
Journal:  Trop Med Int Health       Date:  2015-02-03       Impact factor: 2.622

7.  Ebola virus disease: from epidemiology to prophylaxis.

Authors:  Wen Bin Liu; Zi Xiong Li; Yan Du; Guang Wen Cao
Journal:  Mil Med Res       Date:  2015-03-10

8.  Ebola cases and health system demand in Liberia.

Authors:  John M Drake; RajReni B Kaul; Laura W Alexander; Suzanne M O'Regan; Andrew M Kramer; J Tomlin Pulliam; Matthew J Ferrari; Andrew W Park
Journal:  PLoS Biol       Date:  2015-01-13       Impact factor: 8.029

9.  Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control.

Authors:  Cordelia E M Coltart; Anne M Johnson; Christopher J M Whitty
Journal:  BMC Med       Date:  2015-10-19       Impact factor: 8.775

Review 10.  A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection.

Authors:  Hilary Bower; Judith R Glynn
Journal:  Sci Data       Date:  2017-01-31       Impact factor: 6.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.